
MindMed Inc. (NASDAQ:MNMD) reported favorable results for one of its proprietary compounds.
The Phase 1 trial of MM-110 included 108 healthy volunteers and was designed to study the pharmacokinetics and neurocognitive effects of the substance, ensuring its safety and tolerability. MM-110 is designed to treat opioid withdrawal.